BioPharma Credit Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Transaction-Based Revenues	139.75	148.63	155.36	211.08	127.62
Other Revenues	18.04	1.4	-19.63	7.06	-23.75
Revenue	157.78	150.03	135.73	218.14	103.86
Revenue Growth (YoY)	5.17%	10.53%	-37.78%	110.03%	-5.59%
Cost of Revenue	25.73	25.57	25.24	33.9	15.89
Gross Profit	132.06	124.46	110.49	184.25	87.97
Selling, General & Admin	2.17	2.28	2.04	1.93	3.01
Operating Income	129.89	122.18	108.45	182.31	84.96
Pretax Income	129.89	122.18	108.45	182.31	84.96
Net Income	129.89	122.18	108.45	182.31	84.96
Net Income to Common	129.89	122.18	108.45	182.31	84.96
Net Income Growth	6.31%	12.66%	-40.51%	114.59%	-4.69%
Shares Outstanding (Basic)	1,140	1,222	1,309	1,364	1,374
Shares Outstanding (Diluted)	1,140	1,222	1,309	1,364	1,374
Shares Change (YoY)	-6.77%	-6.65%	-4.00%	-0.72%	-0.00%
EPS (Basic)	0.11	0.10	0.08	0.13	0.06
EPS (Diluted)	0.11	0.10	0.08	0.13	0.06
EPS Growth	14.11%	20.65%	-38.02%	116.18%	-4.78%
EBIT	129.89	122.18	108.45	182.31	84.96